For older patients with small (T1a) renal cancer, percutaneous ablation is associated with much lower costs than partial or radical nephrectomy, according to Adam D. Talenfeld, M.D. Read more
Certain types of cancer may be even more shifty and difficult to target than previously thought, due to continuous changes in cell programming. Read more
Despite very promising pre-clinical results and some clinical success, there is still much need to generate solid evidence demonstrating the efficacy of combining radiation with immunotherapy, according to Silvia Formenti, M.D., and Sandra Demaria, M.D. Read more
A drug that recruits immune cells to fight an aggressive form of lymphoma that disproportionately affects minorities in the United States appears to be more effective than chemotherapy, according to Adrienne Phillips, M.D. Read more
Metastatic prostate cancer patients respond better to treatment when they switch to different drugs in the absence of an optimal initial response, according to Scott Tagawa, M.D. and Paraskevi Giannakakou, Ph.D. Read more
Ruben Niesvizky, M.D., comments on a study that tested a new drug combination (daratumumab+bortezomib+dexamethasone) to treat multiple myeloma Read more
Discussing re-staging scan results with oncologists—rather than other care-team members—may lead to a better understanding of late- or end-stage disease in patients with advanced cancers. Read more